Cargando…

The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin

OBJECTIVE: Type 2 diabetes mellitus (T2DM) is a chronic condition complicated by being overweight or obese. This study used a patient survey to assess health, satisfaction, and diabetes self-management in relation to weight management. METHODS: A survey including the Current Health Satisfaction Ques...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerlanc, Nicole M, Cai, Jennifer, Tkacz, Joseph, Bolge, Susan C, Brady, Brenna L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365331/ https://www.ncbi.nlm.nih.gov/pubmed/28360528 http://dx.doi.org/10.2147/DMSO.S129824

Ejemplares similares

Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes
por: Bolge, Susan C, et al.
Publicado: (2017)

Assessment of Rheumatoid Arthritis Quality Process Measures and Associated Costs
por: Brady, Brenna L., et al.
Publicado: (2017)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
por: Triplitt, Curtis, et al.
Publicado: (2015)

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
por: Wysham, Carol H., et al.
Publicado: (2017)

The Burden of Poor Mental Well-being Among Patients With Type 2 Diabetes Mellitus: Examining Health Care Resource Use and Work Productivity Loss
por: Bolge, Susan C., et al.
Publicado: (2016)

Increasing rate of diagnosed childhood mental illness in the United States: Incidence, prevalence and costs
por: Tkacz, Joseph, et al.
Publicado: (2021)

The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss
por: Bell, David S.H.
Publicado: (2014)

Effects of canagliflozin on weight loss in high-fat diet-induced obese mice
por: Ji, Wenjun, et al.
Publicado: (2017)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
por: Yagi, Shusuke, et al.
Publicado: (2017)

Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS)
por: Hassanein, Mohamed, et al.
Publicado: (2017)

Patient engagement in type 2 diabetes mellitus research: what patients want
por: Simacek, Kristina F, et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India
por: Prasanna Kumar, K. M., et al.
Publicado: (2016)

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
por: Davies, M. J., et al.
Publicado: (2015)

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
por: Budoff, Matthew J., et al.
Publicado: (2017)

An Assessment of the AGA and CCFA Quality Indicators in a Sample of Patients Diagnosed with Inflammatory Bowel Disease
por: Tkacz, Joseph, et al.
Publicado: (2015)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates
por: John, Mathew, et al.
Publicado: (2016)

Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus
por: Kuo, Hsiao-Huai, et al.
Publicado: (2023)

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
por: Bays, Harold E, et al.
Publicado: (2014)

Patient profiling in diabetes and role of canagliflozin
por: Amblee, Ambika
Publicado: (2014)

The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
por: Carbone, Salvatore, et al.
Publicado: (2019)

Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus
por: Wang, Limin, et al.
Publicado: (2023)

Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor–Induced Hyperglycemia: A Case Report
por: Bowman, Christopher, et al.
Publicado: (2017)

A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
por: Nardolillo, AnneMarie, et al.
Publicado: (2014)

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes
por: Ali, Ali Muhammed, et al.
Publicado: (2020)

Efficacy and Safety of Canagliflozin in Kidney Transplant Patients
por: Shah, Mita, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting
por: Baruah, Manash P., et al.
Publicado: (2016)

Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis
por: Buysman, Erin K., et al.
Publicado: (2015)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies, Michael J, et al.
Publicado: (2017)

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
por: Rodbard, H. W., et al.
Publicado: (2016)

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
por: Tanaka, Hiroyuki, et al.
Publicado: (2016)

A Case of Fournier’s Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus
por: Elbeddini, Ali, et al.
Publicado: (2020)

Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS
por: Borisov, Angel N, et al.
Publicado: (2023)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Management of diabetes mellitus in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon
por: Sehgal, Vishal, et al.
Publicado: (2014)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis
por: Kaur, Kirandeep, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1ebjm662s8sovv2kn77g144elr